Covid-19 vaccine: Supplying Covaxin at Rs 150/dose to Centre ‘not sustainable’ in long run, says Bharat Biotech

[ad_1]


Talking about the higher pricing of Covaxin for private sector players, the company said this is purely due to fundamental business reasons.

[ad_2]

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Polynion

Binance Prediction

Metamask

papamiaspizza.com

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99